Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib

Vasiliki-Kalliopi Bournia, Oliver Distler, Evrydiki Kravvariti, Dimos Mitsikostas, Petros P. Sfikakis
European Respiratory Journal 2021 57: 2003021; DOI: 10.1183/13993003.03021-2020
Vasiliki-Kalliopi Bournia
1Joint Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Distler
2Dept of Rheumatology, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evrydiki Kravvariti
1Joint Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Evrydiki Kravvariti
Dimos Mitsikostas
1Joint Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dimos Mitsikostas
Petros P. Sfikakis
1Joint Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Extract

Nocebo effects, the opposite of placebo effects, are defined as unfavourable changes in a patient's symptoms or condition occurring due to negative anticipation and possibly leading to suboptimal outcomes via treatment discontinuation or non-adherence [1]. Symptoms most commonly associated with nocebo in both dedicated neurobiological research and randomised controlled trial (RCT) settings are non-specific complaints, such as pain, malaise, dizziness or gastrointestinal upset [2]. Despite evidence highlighting the implications of placebo and nocebo effects on daily practice and RCT design and interpretation, determining their true frequency and intensity remains a challenge [1, 2].

Abstract

Nocebo effects may partly account for the high rates of diarrhoea reported in scleroderma patients enrolled in nintedanib RCTs. Investing in the doctor–patient relationship and improved informed consent procedures can reduce nocebo phenomena in trials. https://bit.ly/2VyoVhi

Footnotes

  • Conflict of interest: V-K. Bournia reports grants from Boehringer Ingelheim and GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: O. Distler reports grants and personal fees from Bayer, Boehringer Ingelheim and Mitsubishi Tanabe Pharma, personal fees from Abbvie, Acceleron Pharma, Amgen, AnaMar, Catenion, Drug Development International Ltd, CSL Behring, ChemomAb, GSK, Horizon (Curzion) Pharmaceuticals, Inventiva, Italfarmaco, iQvia, Lilly, Medac, Medscape, MSD, Novartis, Pfizer, Roche, Sanofi, Serodapharm, Target Bio Science and UCB, outside the submitted work; and has a patent US8247389, EP2331143 issued.

  • Conflict of interest: E. Kravvariti has nothing to disclose.

  • Conflict of interest: D. Mitsikostas has nothing to disclose.

  • Conflict of interest: P.P. Sfikakis reports grants and personal fees from Actelion, grants from Boehringer Ingelheim, outside the submitted work.

  • Received August 4, 2020.
  • Accepted November 30, 2020.
  • Copyright ©ERS 2021
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 4 Table of Contents
European Respiratory Journal: 57 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib
Vasiliki-Kalliopi Bournia, Oliver Distler, Evrydiki Kravvariti, Dimos Mitsikostas, Petros P. Sfikakis
European Respiratory Journal Apr 2021, 57 (4) 2003021; DOI: 10.1183/13993003.03021-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib
Vasiliki-Kalliopi Bournia, Oliver Distler, Evrydiki Kravvariti, Dimos Mitsikostas, Petros P. Sfikakis
European Respiratory Journal Apr 2021, 57 (4) 2003021; DOI: 10.1183/13993003.03021-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Erythrocytes are altered in PAH
  • Long COVID symptoms, from an imaginary condition to a recognised syndrome
  • Dupilumab in patients with asthma and blood eosinophils ≥500 cells·µL−1
Show more Agora

Research letters

  • Erythrocytes are altered in PAH
  • Dupilumab in patients with asthma and blood eosinophils ≥500 cells·µL−1
  • NTM-PD incidence among elderly patients with bronchiectasis
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society